BMJ1d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ2d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ3d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ3d
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into ...
BMJ5d
It is time to rethink juvenile idiopathic arthritis classification and nomenclature
Correspondence to Alberto Martini, University of Genoa, Pediatria II, Istituto G Gaslini, Largo Gaslini 5, Genova 16147, Italy; albertomartini{at}ospedale-gaslini.ge.it Juvenile idiopathic arthritis ...
BMJ6d
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Objective To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods Fifty-three patients with active disease from an ongoing ...
BMJ6d
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis
Objectives Nerve growth factor (NGF) has emerged as a key driver of pain in osteoarthritis (OA) and antibodies to NGF are potent analgesics in human disease. Here, we validate a novel vaccine strategy ...
BMJ7d
Vascular occlusion for optimising the functional improvement in patients with knee osteoarthritis: a randomised controlled trial
Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
BMJ9d
Evidence that autoantibody production may be driven by acute Epstein-Barr virus infection in Sjögren’s disease
Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...
BMJ12d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ12d
Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis
Objective Epidemiological studies of primary Sjögren's syndrome (pSS) are crucial for describing the burden to society and the public medical system and for shedding light on aetiology. Previous ...
BMJ12d
Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study
1 Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands 2 Orthopaedics, University Medical Center Utrecht, Utrecht, The Netherlands 3 Institute of Anatomy ...